Channing Capital Management LLC Takes $6.19 Million Position in Becton, Dickinson and Company (NYSE:BDX)

Channing Capital Management LLC acquired a new stake in Becton, Dickinson and Company (NYSE:BDX) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 25,374 shares of the medical instruments supplier’s stock, valued at approximately $6,187,000.

Several other hedge funds also recently added to or reduced their stakes in BDX. Value Partners Investments Inc. grew its stake in Becton, Dickinson and Company by 5.2% during the 3rd quarter. Value Partners Investments Inc. now owns 867 shares of the medical instruments supplier’s stock valued at $225,000 after purchasing an additional 43 shares in the last quarter. Dover Advisors LLC increased its stake in shares of Becton, Dickinson and Company by 1.7% in the third quarter. Dover Advisors LLC now owns 2,702 shares of the medical instruments supplier’s stock worth $699,000 after buying an additional 45 shares during the last quarter. Mendel Money Management raised its holdings in Becton, Dickinson and Company by 3.0% in the third quarter. Mendel Money Management now owns 1,536 shares of the medical instruments supplier’s stock valued at $397,000 after acquiring an additional 45 shares in the last quarter. Phillips Wealth Planners LLC boosted its stake in Becton, Dickinson and Company by 6.0% during the 3rd quarter. Phillips Wealth Planners LLC now owns 818 shares of the medical instruments supplier’s stock valued at $211,000 after acquiring an additional 46 shares during the last quarter. Finally, CWM LLC grew its holdings in Becton, Dickinson and Company by 0.7% during the 4th quarter. CWM LLC now owns 6,303 shares of the medical instruments supplier’s stock worth $1,537,000 after acquiring an additional 46 shares in the last quarter. 86.97% of the stock is currently owned by hedge funds and other institutional investors.

Becton, Dickinson and Company Stock Performance

NYSE BDX traded up $1.09 during trading hours on Monday, reaching $235.77. The company’s stock had a trading volume of 666,150 shares, compared to its average volume of 1,404,475. The company has a current ratio of 1.41, a quick ratio of 0.97 and a debt-to-equity ratio of 0.62. The business has a 50-day simple moving average of $238.45 and a 200 day simple moving average of $240.27. Becton, Dickinson and Company has a 52 week low of $229.40 and a 52 week high of $287.32. The stock has a market cap of $68.14 billion, a PE ratio of 52.12, a PEG ratio of 1.92 and a beta of 0.45.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Thursday, May 2nd. The medical instruments supplier reported $3.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.97 by $0.20. The business had revenue of $5.05 billion for the quarter, compared to the consensus estimate of $5.04 billion. Becton, Dickinson and Company had a return on equity of 13.90% and a net margin of 6.76%. The business’s revenue was up 4.6% on a year-over-year basis. During the same quarter last year, the business posted $2.86 EPS. Equities research analysts predict that Becton, Dickinson and Company will post 13.04 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 28th. Stockholders of record on Monday, June 10th will be given a dividend of $0.95 per share. The ex-dividend date of this dividend is Monday, June 10th. This represents a $3.80 annualized dividend and a dividend yield of 1.61%. Becton, Dickinson and Company’s dividend payout ratio is currently 83.70%.

Wall Street Analyst Weigh In

Separately, Barclays increased their price target on shares of Becton, Dickinson and Company from $305.00 to $312.00 and gave the stock an “overweight” rating in a research report on Monday. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, Becton, Dickinson and Company presently has an average rating of “Moderate Buy” and an average price target of $281.40.

Insider Buying and Selling

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,715 shares of the company’s stock in a transaction dated Tuesday, April 30th. The shares were sold at an average price of $232.81, for a total value of $399,269.15. Following the completion of the transaction, the executive vice president now owns 5,381 shares in the company, valued at approximately $1,252,750.61. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, SVP Thomas J. Spoerel sold 282 shares of the company’s stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $238.29, for a total value of $67,197.78. Following the completion of the sale, the senior vice president now owns 2,276 shares of the company’s stock, valued at $542,348.04. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Michael David Garrison sold 1,715 shares of the firm’s stock in a transaction dated Tuesday, April 30th. The shares were sold at an average price of $232.81, for a total transaction of $399,269.15. Following the transaction, the executive vice president now directly owns 5,381 shares in the company, valued at approximately $1,252,750.61. The disclosure for this sale can be found here. Corporate insiders own 0.31% of the company’s stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.